Incyte Corporation Earnings

The next earnings date for Incyte Corporation is July 28, 2025.

They are scheduled to announce earnings before the market opens that day.

Analyst Estimates of Incyte Corporation Earnings

Report DateEstimated Earnings Per Share
11/04/2025$1.53
07/28/2025$1.40

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Incyte Corporation Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
04/28/2025Before Market$1.1638.10%
02/11/2025Before Market$1.43-8.01%
10/29/2024Before Market$1.070.00%
07/30/2024Before Market$-1.82-17.42%
04/30/2024Before Market$0.64-23.81%
02/13/2024Before Market$1.06-8.62%
10/31/2023Before Market$1.107.84%
08/01/2023Before Market$0.9919.28%
05/02/2023Before Market$0.37-51.32%
02/07/2023Before Market$0.626.90%
11/01/2022Before Market$0.60-16.67%
08/02/2022Before Market$1.0132.89%
05/03/2022Before Market$0.55-17.91%
02/08/2022Before Market$0.10-88.51%
11/02/2021Before Market$1.1857.33%
08/03/2021Before Market$0.808.11%
05/04/2021Before Market$0.674.69%
02/09/2021Before Market$0.9324.00%
11/05/2020Before Market$0.23-69.33%
08/04/2020Before Market$1.2442.53%
05/05/2020Before Market$-2.86-568.85%
02/13/2020Before Market$0.6514.04%
10/29/2019Before Market$0.8226.15%
07/30/2019Before Market$0.7556.25%
04/30/2019Before Market$0.6255.00%
02/14/2019Before Market$0.40-13.04%
10/30/2018Before Market$0.38-5.00%
07/31/2018Before Market$0.26-23.53%
05/01/2018Before Market$-0.01-125.00%
02/15/2018Before Market$-0.71-57.78%
10/31/2017Before Market$0.0814.29%
08/01/2017Before Market$-0.06-20.00%
05/04/2017Before Market$-0.6832.00%
02/14/2017Before Market$0.05-61.54%
11/01/2016Before Market$0.192,000.00%
08/09/2016Before Market$0.191,050.00%
05/09/2016Before Market$0.12-29.41%
02/11/2016Before Market$0.29222.22%
11/03/2015Before Market$-0.2246.34%
08/04/2015Before Market$-0.0918.18%
04/30/2015Before Market$-0.11-10.00%
02/12/2015Before Market$-0.22-144.44%
10/30/2014Before Market$0.333,200.00%
07/31/2014---$-0.22-450.00%
05/01/2014---$-0.21-16.67%
02/12/2014---$-0.15-36.36%
10/31/2013---$-0.14-7.69%
08/01/2013---$0.05-37.50%
05/02/2013---$-0.1236.84%
02/14/2013---$0.14800.00%
11/01/2012---$-0.1719.05%
08/02/2012---$0.03---
04/26/2012---$-0.3621.74%
02/15/2012---$-0.44-12.82%
10/27/2011---$-0.426.67%
07/28/2011---$-0.41-13.89%
05/03/2011---$-0.2134.38%
02/10/2011---$0.2426.32%
11/09/2010---$-0.2618.75%
08/05/2010---$0.02150.00%
05/06/2010---$-0.306.25%
02/18/2010---$-0.41-13.89%
11/05/2009---$-0.44-10.00%
07/30/2009---$-0.410.00%
05/07/2009---$-0.410.00%
02/18/2009---$-0.50-4.17%
11/06/2008---$-0.484.00%
07/29/2008---$-0.54-8.00%
04/30/2008---$-0.470.00%
02/14/2008---$-0.267.14%
11/01/2007---$-0.29-7.41%
07/26/2007---$-0.2218.52%
05/03/2007---$-0.260.00%
02/15/2007---$-0.244.00%
11/02/2006---$-0.1920.83%
07/27/2006---$-0.240.00%
05/04/2006---$-0.2119.23%
02/16/2006---$-0.33-6.45%
11/01/2005---$-0.365.26%
08/01/2005---$-0.309.09%
05/04/2005---$-0.2427.27%
02/28/2005---$-0.47-34.29%
11/04/2004---$-0.3518.60%
08/04/2004---$-0.87-117.50%
05/04/2004---$-0.52-15.56%
02/02/2004---$-0.56-14.29%
11/04/2003---$-0.60-53.85%
07/30/2003---$-0.375.13%
05/05/2003---$-0.36-28.57%
02/19/2003---$-0.45-15.38%
11/12/2002---$-0.45-21.62%
07/25/2002---$-0.267.14%
05/01/2002---$-0.204.76%
02/13/2002---$-0.2271.05%
10/25/2001---$-0.27-42.11%
07/19/2001---$-0.1534.78%
04/25/2001---$-0.1642.86%
02/01/2001---$-0.118.33%
10/17/2000---$-0.120.00%
07/18/2000---$-0.1054.55%
04/19/2000---$-0.1353.57%
01/26/2000---$-0.118.33%
10/19/1999---$-0.190.00%
07/14/1999---$-0.110.00%
04/21/1999---$-0.0450.00%
02/03/1999---$0.1220.00%
10/14/1998Before Market$0.08-20.00%
07/14/1998Before Market$0.1011.11%
04/08/1998Before Market$0.080.00%
01/13/1998Before Market$0.0928.57%
10/15/1997Before Market$0.060.00%
07/15/1997Before Market$0.040.00%
04/17/1997---$0.02-33.33%
02/26/1997---$0.010.00%
10/24/1996---$0100.00%
07/25/1996---$-0.04-33.33%
04/25/1996---$-0.040.00%
02/21/1996---$-0.060.00%
10/25/1995---$-0.09-50.00%

More About Incyte Corporation

Website
https://www.incyte.com
Country
USA
Full Time Employees
2,617

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

“Incyte Corporation Earnings” Can Refer to the Incyte Corporation Earnings Date

Some people say “Incyte Corporation earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Incyte Corporation position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Incyte Corporation Stock on the Earnings Date

If you own Incyte Corporation stock (INCY) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Incyte Corporation might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Incyte Corporation shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Incyte Corporation Earnings

You can contact us any time if you would like to ask questions about Incyte Corporation earnings or anything else related to the stock market.